By Fineline Cube 
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its biosimilar version of Denmark-based Novo Nordisk’s (NYSE: NVO) human growth hormone Norditropin (somatropin).
Biosimilar Profile
Yifan Pharma’s Category 3.3 therapeutic biologic product is identical to natural human growth hormone in terms of amino acid sequence. This biosimilar can now be assessed for use in pediatric growth disorders, including growth hormone deficiency (GHD), Turner syndrome, chronic kidney disease (CKD)-associated growth failure, and Noonan syndrome. It will also be evaluated for adult-onset or childhood-onset GHD persisting into adulthood.-Fineline Info & Tech